Study of 177Lu-JH04 for tumors with FAP protein
Part of Cancer clinical trials.
This trial tests a radioactive drug called 177Lu-JH04 for people whose tumors have high levels of a protein called FAP. The drug targets and treats advanced tumors that have stopped responding to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced, metastatic, and getting worse despite treatment.
- A special PET scan must show your tumors have high levels of the FAP protein.
- Your kidneys, blood cells, and liver must be working well enough.
- You must be able to do most daily activities on your own (ECOG score 0-2).
- You cannot be pregnant or breastfeeding.
- You must not have had any radiation therapy or other cancer treatment in the past 28 days, and no other radioactive treatment in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new radioactive drug that targets a protein called FAP on cancer cells. It is for people with advanced stomach, pancreas, colon, bile duct, or esophageal cancers that have spread and show high FAP levels on a special scan.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
Hear when a new Patients with Advanced Metastatic FAP-Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.